Allergy Therapeutics PLC (AIM:AGY, FRA:HHU) announced encouraging secondary endpoint results from a study of its short-course peanut allergy vaccine candidate “VLP Peanut”.
The secondary endpoint results from the ex-vivo biomarker study VLP001 demonstrated a reduced IgE binding capacity to B cells of VLP Peanut, suggesting a promising safety profile with reduced potency to induce allergic reactions.
Allergy Therapeutics said the results provide a strong indication for the products' efficacy potential, adding “these results provide strong confidence in the beneficial immunologic mode of action of VLP Peanut”.
“In combination with the primary outcome data, these secondary endpoint results are encouraging and provide strong support for the human translation of the pre-clinical results and strong confidence in the data to be generated in the planned Phase I PROTECT study,” the company said.
The Phase I PROTECT study is expected to start in the first quarter of 2022.
Commenting on the results, Allergy Therapeutics CEO Manuel Llobet stated: "We are pleased to see such encouraging secondary endpoint data, following the primary endpoint that we announced just a few weeks ago.
“These ex-vivo data, using human cells, clearly suggest that the vaccine candidate does not only have hypoallergic potential but also has the ability to induce a protective immune-response upon administration. This is a vital step in our journey to provide a safe and sustained effective treatment solution to those affected by peanut allergy; we look forward to progressing with the clinical programme and to initiate the PROTECT study in 2022.”
READ: Allergy Therapeutics announces successful primary outcome of VLP Peanut 001 study